-
Tytuł:
-
A latent class analysis of psychiatric symptom profiles associated with past-month methamphetamine use.
-
Autorzy:
-
Voce A; Centre for Research on Ageing, Health and Wellbeing, Australian National University, Building 54, Mills Road, Acton, ACT 2601, Australia. Electronic address: .
Burns R; Centre for Research on Ageing, Health and Wellbeing, Australian National University, Building 54, Mills Road, Acton, ACT 2601, Australia.
Castle D; Centre for Complex Interventions, Centre for Addictions and Mental Health, Toronto, Canada; University of Toronto, Toronto, Canada.
Calabria B; Research School of Population Health, Australian National University, Building 54, Mills Road, Acton, ACT 2601, Australia; National Drug and Alcohol Research Centre, University of New South Wales, 22 King Street, Randwick, NSW 2031, Australia.
McKetin R; National Drug and Alcohol Research Centre, University of New South Wales, 22 King Street, Randwick, NSW 2031, Australia.
-
Źródło:
-
Psychiatry research [Psychiatry Res] 2021 Apr; Vol. 298, pp. 113760. Date of Electronic Publication: 2021 Jan 27.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Limerick : Elsevier/North-Holland Biomedical Press
Original Publication: Amsterdam, Elsevier/North-Holland Biomedical Press.
-
MeSH Terms:
-
Amphetamine-Related Disorders*
Methamphetamine*/adverse effects
Psychoses, Substance-Induced*/diagnosis
Psychoses, Substance-Induced*/etiology
Hallucinations/chemically induced ; Humans ; Latent Class Analysis
-
Contributed Indexing:
-
Keywords: Amphetamine; Drug-induced; Methamphetamine-associated; Methamphetamine-related; Schizophrenia; Stimulants; Substance-induced
-
Substance Nomenclature:
-
44RAL3456C (Methamphetamine)
-
Entry Date(s):
-
Date Created: 20210206 Date Completed: 20210819 Latest Revision: 20210819
-
Update Code:
-
20240104
-
DOI:
-
10.1016/j.psychres.2021.113760
-
PMID:
-
33548691
-
We explored latent psychiatric symptom profiles associated with methamphetamine use, and examined how these corresponded to diagnoses of schizophrenia (SZ) and methamphetamine-associated psychosis (MAP). We assessed psychiatric symptoms among 160 people who had used methamphetamine in the past month. Psychiatric symptoms were defined as a score of 4+ on Brief Psychiatric Rating Scale (BPRS) items. Diagnoses were made using the Composite International Diagnostic Interview (CIDI). Participants were defined as having MAP if they met symptom criteria for SZ, but symptoms were considered to be always the result of substance use. Latent class analysis identified three classes. Class one (44% of participants) had a low probability of most BPRS symptoms; 4% met criteria for SZ, 51% for MAP. Class two (31% of participants) had a higher probability hallucinations and suspiciousness (37-46%); 72% met criteria for MAP, and 7% for SZ. Class three (25% of participants) had the highest probability for all positive psychotic symptoms (hallucinations, suspiciousness, grandiosity, unusual thought content; 32-82%), and reported activation, conceptual disorganisation, and tension (35% met criteria for SZ and 17% for MAP). We found three distinct classes of psychiatric symptom profiles, two of which showed partial alignment with diagnostic constructs of SZ and MAP.
(Copyright © 2021. Published by Elsevier B.V.)
